Second Affiliated Hospital of Guangzhou Medical University
Phase
Phase 1
Started
2021-03-01
Last updated
2024-06-26
Condition(s) studied
Lung CancerHepatocellular CarcinomaSolid Tumor
Investigational drug(s) / intervention(s)
CpG-ODN
CpG-ODN: CAR-T cells secreting scFv against OX40
Study summary
To study the safety and clinical effects of intratumor injecting CpG-ODN and in situ release of tumor antigen by interventional ablation or drug-eluting beads to treat advanced solid tumors.
Eligibility
Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria:
* Solid advanced malignant tumors
* Age between18 and 80 years
* Life expectancy is greater than three months
Exclusion Criteria:
* Benign tumor
* Life expectancy is less than three months
* Serious medical comorbidity
* Others
Primary outcome measure(s)
Assessing safety and treatment efficacy on intratumor injection of CpG-ODN and in situ tumor antigen release for advanced tumors — up to 36 months Assessing incidence of side effects and primary clinical response of the intratumor injection of CpG-ODN and therpeutical in situ tumor antigen release for advanced tumors, including CR, PR, SD, and PD.
Trial sites (1)
Facility
City
Region
Status
The Second Affiliated Hospital of Guangzhou Medical University
Guangzhou
Guangdong
Recruiting
More Second Affiliated Hospital of Guangzhou Medical University trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.